- Home
- PB vs SLGL Comparison
PB vs SLGL Comparison
Compare PB & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PB | SLGL |
|---|---|---|
| Founded | 1983 | 1997 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 159.7M |
| IPO Year | 1998 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PB | SLGL |
|---|---|---|
| Price | $72.93 | $70.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 1 |
| Target Price | $79.38 | ★ $110.00 |
| AVG Volume (30 Days) | ★ 1.6M | 27.2K |
| Earning Date | 01-28-2026 | 11-20-2025 |
| Dividend Yield | ★ 3.22% | N/A |
| EPS Growth | ★ 13.34 | N/A |
| EPS | ★ 5.72 | N/A |
| Revenue | ★ $1,249,793,000.00 | $18,970,000.00 |
| Revenue This Year | $36.58 | $122.71 |
| Revenue Next Year | $14.41 | N/A |
| P/E Ratio | $13.02 | ★ N/A |
| Revenue Growth | 5.63 | ★ 62.04 |
| 52 Week Low | $61.07 | $4.02 |
| 52 Week High | $79.03 | $76.80 |
Technical Indicators
Market Signals| Indicator | PB | SLGL |
|---|---|---|
| Relative Strength Index (RSI) | 52.61 | 73.05 |
| Support Level | $65.12 | $62.23 |
| Resistance Level | $77.20 | $67.78 |
| Average True Range (ATR) | 2.11 | 6.33 |
| MACD | 0.26 | 0.20 |
| Stochastic Oscillator | 66.66 | 96.81 |
Price Performance
Historical ComparisonAbout PB Prosperity Bancshares Inc.
Prosperity Bancshares Inc provides retail and commercial banking services to individuals and small to midsize businesses. It provides a wide array of financial products and services to businesses and consumers throughout Texas and Oklahoma. The group provides Personal, Business, Mortgage, and Banking Services.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.